North America Syndromic Multiplex Diagnostic Market - By Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection Type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis Panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others) Industry Trends and Forecast to 2029.
Market Definition and Insights
Syndromic multiplex diagnostic is a type of advanced diagnostic test utilised to detect infectious diseases such as respiratory infection, infective gastroenteritis, sexually transmitted infections, sepsis, and meningitis, among other types of infectious diseases. The syndromic multiplex diagnostic also helps the clinicians or hospitals to detect the symptoms and signs of the various types of diseases. This lets the health care providers provide the right treatment for the patients and offer more precise outcomes and care that can be performed more quickly.
Syndromic multiplex testing is used to diagnose many pathogens simultaneously. In the syndromic multiplex diagnostic, various types of reagents & consumables and instruments & accessories are used, which helps maintain accuracy and provide fast diagnosis results. These multiplex tests are rapidly diagnosed with certain infections, allowing clinical management decisions to be made promptly. The tests based on multiplex technology are known as test panels. The panels used in syndromic testing are designed to diagnose multiple diseases associated with the same or similar syndrome type. These panels help evaluate the cause of the disease at the point of care. Gastrointestinal panels and respiratory panels are the types of syndromic panels.
Syndromic multiplex testing utilizes the advanced technology of multiplex PCR which provides accurate and fast diagnostic results with the help of the multiple panels used in syndromic multiplex diagnostic to provide diagnostic results within an hour. The new generations of syndromic multiplex can rapidly identify the common type of pathogens in the respiratory specimens, blood and cerebrospinal. The use of multiplex panels is associated with quicker turnaround time, reduction of other unnecessary laboratory tests, faster diagnosis and targeted treatment.
Data Bridge Market Research analyses that the North America syndromic multiplex diagnostic market will grow at a CAGR of 9.0% during the forecast period of 2022 to 2029.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection Type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico
|
|
Market Players Covered
|
BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc. (South Korea), Luminex Corporation. A DiaSorin Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cepheid (A subsidiary of Danaher (U.S.)), QIAGEN (Germany), Abbott (U.S.), Hologic, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Siemens Healthcare GmbH (Germany), Akonni Biosystems, Inc. (U.S.), Biocartis (Belgium), QuantuMDx Group Ltd. (U.K.), Applied BioCode, Inc. (U.S.), Prominex Inc. (U.S.), Nanomix, Inc. (U.S.), Curetis (A subsidiary of OpGen, Inc.) (Germany)
|
Syndromic Multiplex Diagnostic Market Dynamics
Drivers
- Rise in prevalence of infectious diseases
The rising incidence of infectious bacterial and viral diseases impacts the market's demand because, in the syndromic testing, multiplex real-time PCR technique and the syndromic approach are used for molecular diagnostics of infectious diseases.
- Increase in regulatory approval for acute respiratory syndrome coronavirus testing
In May 2020, biomérieux SA received FDA Emergency Use Authorization (EUA) for the BIOFIRE RP2.1 panel, which is used for the detection of 22 pathogens which is causing respiratory infections, including SARS-CoV-2 for COVID-19 disease.
The regulatory authorities, such as the FDA or CE mark, provide Emergency Use Authorization (EUA) approval for commercializing SARS-CoV-2 panels and testing to detect viruses associated with COVID-19 disease, which is a driver for the growth of the market.
Opportunities
- Strategic Initiatives taken by market players
In March 2021, F. Hoffman-La Roche Ltd acquired GenMark Diagnostics, a leading multiplex molecular diagnostics provider. This acquisition has helped the company to broaden Roche’s molecular diagnostic portfolio. These strategic initiatives taken by the market players, including focused segment product launches, are helping them expand their global reach and enhance their product portfolio and acting as an opportunity for the market's growth.
- Introduction of technologically advanced products
The syndromic multiplex testing utilizes the advanced technology of multiplex PCR to detect, isolate, or amplify targeted nucleic acid to provide accurate and fast diagnostic results; the advanced technology provides a diagnostic result within 45 to 60 min. Hence, the development of technologically advanced products is acting as an opportunity for the market's growth.
Restraint/Challenge
- High Cost of Diagnostic Products
The multiplex syndromic testing applications utilize the real-time Polymerase chain reaction (PCR), which delivers the results with amplification curves and correct values. The instruments used in the syndromic multiplex diagnostic require high maintenance costs. Hence, the high cost of instruments is a challenge for the market.
Post COVID-19 Impact on Syndromic Multiplex Diagnostic market
COVID-19 has positively affected the market. Market players are launching different products for the detection of the SARS-CoV virus. There is an increase in approval of products by regulatory bodies after post COVID-19, which leads to an increase in market growth.
Recent Development
- In March 2021, Luminex Corporation. A Diasorin Company received FDA Emergency Use Authorization and CE mark for expanded NxTAG respiratory panel test. This approval has helped the company to increase its revenue.
Syndromic Multiplex Diagnostic Market Scope
The syndromic multiplex diagnostic market is categorized into five segments: product and services, infection type, disease, panels type, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product and Services
- Reagents & Consumables
- Instruments, Software & Accessories
- Services
Based on products and services, the North America syndromic multiplex diagnostic market is segmented into reagents & consumables, instruments, software & accessories and services.
Infection Type
- Viral
- Bacterial
- Parasites
- Fungal
Based on infection type, the North America syndromic multiplex diagnostic market is segmented into viral, bacterial, parasites and fungal.
Disease
- Respiratory Infection
- Gastroneteritis
- Sexually Transmitted Infections
- Sepsis
- Meningitis
- Others
Based on disease, the North America syndromic multiplex diagnostic market is segmented into respiratory infections, gastroenteritis, sexually transmitted infections, sepsis meningitis and others.
Panels Type
- Respiratory Panel
- GI-Enteric Panel
- Sexually Transmitted Disease Panel
- Blood-Sepsis Panel
- Meningitis Panel
- Others
Based on panels type, the North America syndromic multiplex diagnostic market is segmented into respiratory panel, GI-enteric panel, sexually transmitted disease panel, blood-sepsis panel, meningitis panel and others.
End User
- Hospitals
- Clinical Laboratories
- Pharmaceutical & Biotechnology Companies
- Research Institutes
- Others
Based on end user, the North America syndromic multiplex diagnostic market is segmented into clinical laboratories, hospitals, pharmaceutical & biotechnology companies, research institutes and others.
Syndromic Multiplex Diagnostic Market Regional Analysis/Insights
The syndromic multiplex diagnostic market is analysed and market size insights and trends are provided by country, product and services, infection type, disease, panels type and end user as referenced above.
The countries covered in the report are U.S., Canada, and Mexico.
The U.S. syndromic multiplex diagnostic market is expected to grow due to an increase in the prevalence of infectious diseases and a rise in demand for early and accurate diagnosis.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Syndromic Multiplex Diagnostic Market Share Analysis
The syndromic multiplex diagnostic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Saudi Arabia presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to syndromic multiplex diagnostic market.
Some of the major players operating in the North America syndromic multiplex diagnostic market are BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc., Luminex Corporation. A DiaSorin Company, F. Hoffmann-La Roche Ltd, BD, Bio-Rad Laboratories, Inc., Cepheid (A subsidiary of Danaher), QIAGEN, Abbott, Hologic, Inc., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Akonni Biosystems, Inc., Biocartis, QuantuMDx Group Ltd., Applied BioCode, Inc., Prominex Inc., Nanomix, Inc., Curetis (A subsidiary of OpGen, Inc.) among others.
SKU-